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Introduction 
Draft recommendations by NICE1 did not recommend prescription of unlicensed cannabis-
based products to patients on the NHS. The potential benefits for chronic pain were 
considered too small in relation to costs, and the quality of evidence was rated too low to 
make recommendations for severe treatment-resistant epilepsy.1 At present, the only access to 
cannabis is through prescriptions at private clinics2 (which are prohibitively expensive) or via 
the illicit market (which carries risk of prosecution). Given the strong demands for access to 
these products by patients and their carers3 there is an urgent need to strengthen the evidence 
and to make these products available in cases where they are known to be efficacious and 
safe. 
Cannabis-based medicines vary in their content of delta-9-tetrahydrocannbinol (THC) and 
cannabidiol (CBD) which have contrasting mechanisms of action, efficacy and safety.4 Some 
cannabis-based medicines include a combination of THC and CBD which can interact with 
each other when co-administered.5 Although Randomised Controlled Trial (RCT) evidence is 
stronger for certain formulations (such as CBD for severe treatment-resistant epilepsy4) 
patients have expressed a preference for other treatments such as THC combined with CBD.3 
Gathering evidence for such treatments is a key priority that can be addressed using novel 
RCT designs and patient registries. 
In order to compare varied cannabis-based products efficiently, RCTs can follow adaptive 
designs.6 For example, patients can be initially randomised to one of several treatment arms 
such as THC, CBD, or THC combined with CBD. Interim analysis can eliminate treatment 
arms with poor efficacy or safety at an early stage, while randomisation continues to 
potentially efficacious doses to strengthen the certainty of evidence.  
Cannabis-based products have been investigated for a wide range of possible medical 
indications, some of which may share common pathologies of the endocannabinoid system.7 
Where multiple disorders are characterised by the same underlying mechanism, basket trials8 
can investigate a single targeted intervention across multiple diagnostic categories. 
Alternatively where different mechanisms are known to give rise to a common medical 
diagnosis, umbrella trials8 can stratify patients into different treatment arms based on 
underlying disease mechanism and allocate targeted interventions to each group. 
Stratification can also occur at the level of the individual patient. N-of-1 trials9 use within-
patient, randomized, double-blind, crossover comparisons to compare active and control 
treatments in a cyclical manner. N-of-1 trials can establish cause-effect relationships within 
an individual to identify efficacy and safety, and the results from multiple patients can be 
meta-analysed. N-of-1 trials have been successfully applied to cannabis-based products 
(THC, CBD, or THC combined with CBD) for chronic pain10 and could be used for severe 
treatment-resistant epilepsy. They are ideally suited to specific situations such as treatment 
for compassionate reasons, unlicensed use, and for patients who fail to respond to 
conventional treatments11 making them especially suitable for investigating cannabis-based 
medicines in some patients. Classification of a patient as a “responder”9 on a case-by-case 
basis could offer strong evidence for continued prescription. 
RCTs are not the only source of evidence. There are many examples of pharmacological 
treatments for medical indications approved by the EMA and FDA without RCTs.12 Non-
RCT sources of evidence used to support drug approvals include randomised trials without a 
control group (e.g. different doses of active drug with no placebo), historical control studies, 
and observational studies.12 In cases where cannabis-based medicines are provided on private 
prescription,2 patient registries can be used to generate observational data. Such data can be 
rapidly generated at minimal cost, and may be compiled with registries outside of the UK 
such as Canada and Israel to generate large samples of data providing real-world clinical 
evidence. 
 
Initial public funding to support research on cannabis-based products has been offered 
through dedicated calls from the National Institute of Health Research. However, the House 
of Commons Health and Social Care Committee13 raised concerns about the unwillingness of 
industry to provide cannabis-based products for research or to support or conduct clinical 
trials on their products. Further involvement from industry could increase access to cannabis-
based products in a research context without the excessive costs of private prescriptions to 
patients.2 Providing access to cannabis-based products in a research context could offer 
patients balanced information on their likelihood of benefiting from them according to the 
evidence at present. 
 
The current low certainty of evidence for cannabis-based products alongside clear patient 
demand requires novel solutions. Further RCTs for cannabis-based medicines are urgently 
needed, and novel RCT designs such as N-of-1 trials can provide results that are immediately 
beneficial for both the patient and clinician.9 Like all methodologies, RCTs have their own 
limitations and relying on these alone may result in biased estimates of effect. Data should be 
sought from alternative methods such as observational patient registries and triangulated with 
other methods to develop a robust evidence base.14 
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